Tina Woods is a mission-driven social entrepreneur and system architect bringing diverse stakeholders together in shared endeavours to improve health, working at the cross section of science, technology, investment and policy/government. She is Founder and CEO of Collider Health and works with private, public and third sectors.
She is Founder and CEO of Business for Health, a business-led social venture working with the UK Office for National Statistics to measure and incentivise business contribution health, linking health with economic growth in three key areas as part of a system change approach towards a prevention-based model of health: 1) workforce health; 2) consumer health and 3) community health.
She is Executive Director of the International Institute of Longevity, combining her interest in taking the latest science and technology of longevity into the 'next frontier' of the Human Exposome to understand what drives human healthspan, resilience and flourishing.
She is the Healthy Longevity Champion for the National Innovation Centre for Ageing, co-leading the Quantum Healthy Longevity Innovation Mission and City of Longevity programme.
Tina sits on various advisory groups, including the Steering Committee for the Exposome Moonshot, XPRIZE Global Visioneering Brain Trust, Strategic Advisory Board for the BBSRC Bioscience for an Integrated Understanding of Health, and BSI standards group for AI in health and care. She is also a trustee for the British Society for Research on Ageing.
Tina is the co-founder of Longevity Rave (and DJs as Tina Technotic), a collective of entrepreneurs, scientists, DJs and artists that organise raves around the world using the power of music, joy and connection to bring the generations together to dance and celebrate life and humanity.
Tina was director of the All Party Parliamentary Group for Longevity secretariat (2016-2023)
Tina’s book, ‘Live Longer with AI: How artificial intelligence is helping us extend our healthspan and live better too' was published in October 2020.
She studied genetics at Cornell University in the USA and also has an MBA from Bayes Business School in London.
